Sign inJoin waitlistJoin the waitlist

Uma Borate

Clinical Section Head, Acute Leukemia · Ohio State University Hospital

Credentials: · · · · · · · · ·

History

Acute Leukemia Section · Ohio State University Hospital
Present
Acute Leukemia Section · Ohio State University Hospital
Present
Acute Leukemia Section · The Ohio State University Comprehensive Cancer Center – James
Present

The University of Alabama
2008–2011
Internal Medicine
Jefferson Health Medical Education
2004–2008
University of Cincinnati, Cincinnati, OH
B J MED COLL, GUJARAT UNIV, AHMEDABAD, GUJARAT
1996–2000

Research

Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Cancer Cell · 2022 · 343 citations
NCCN Clinical Practice Guidelines Acute myeloid leukemia
Journal of the National Comprehensive Cancer Network · 2012 · 226 citations

Alice Mims
23 papers
Brian Druker
22 papers
Olatoyosi Odenike
21 papers
JB
John Byrd
18 papers
Andrew Brunner
17 papers
Yazan Madanat
17 papers
AD
Amy DeZern
16 papers
ES
Eytan Stein
16 papers
Ross Levine
16 papers
Tara Lin
16 papers
ET
Elie Traer
15 papers
Gary Schiller
15 papers

Clinical trials

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Principal investigator · Recruiting · Phase 2
Uma Borate
2026–2027
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Principal investigator · Recruiting · Phase 1, Phase 2
Uma Borate
2024–2028
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Principal investigator · Recruiting · Phase 1
Uma Borate
2024–2027
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Principal investigator · Recruiting · Phase 2
Uma Borate
2023–2028